Triumeq PD

abacavir/ dolutegravir/ lamivudine

Drug Monograph

Black Box Warnings
Adult Dosing
Peds Dosing
Contraindications/Cautions
Drug Interactions
Adverse Reactions
Safety/Monitoring
Pregnancy/Lactation
Pharmacology
Formulary
Manufacturer/Pricing
Patient Education
Pill Pictures
Add to Interaction Check
Dosing Calculator

Black Box Warnings .

Hypersensitivity Reaction

serious or fatal hypersensitivity reaction have occurred with abacavir-containing products; abacavir hypersensitivity is a multi-organ clinical syndrome; HLA-B*57:01 allele carriers at higher risk of hypersensitivity reactions; abacavir/dolutegravir/lamivudine contraindicated in HLA-B*57:01-positive patients or in patients with prior hypersensitivity reaction to abacavir; permanently D/C if hypersensitivity reaction suspected or cannot be ruled out, regardless of HLA-B*57:01 status; NEVER restart any abacavir-containing products after hypersensitivity reaction

Hepatitis B Exacerbation

all patients with HIV infection should be tested for HBV before starting abacavir/dolutegravir/lamivudine; lamividine-resistant HBV variants associated with lamivudine-containing regimens reported; consider additional tx for chronic HBV tx if abacavir/dolutegravir/lamivudine used in HBV/HIV co-infected patients, or consider alternative regimen; severe acute HBV exacerbations in HBV/HIV co-infected patients upon lamivudine D/C; monitor hepatic function closely for at least several months in HBV/HIV co-infected patients who D/C abacavir/dolutegravir/lamivudine; initiate anti-HBV tx if needed

Adult Dosing .

Adult dosing is currently unavailable or not applicable for this drug.

Peds Dosing .

Dosage forms: DISPERSE TAB: 60 mg/5 mg/30 mg

Special Note

[equivalency or interchangeability info]: Info: not interchangeable with abacavir/dolutegravir/lamivudine tabs; do not substitute on a mg to mg basis

HIV infection

[3 mo and older, 6-9 kg]: Dose: 3 tabs PO qd; Info: D/C drug and do not restart if hypersensitivity reaction suspected; do not cut/crush/chew tab or swallow tab whole

[3 mo and older, 10-13 kg]: Dose: 4 tabs PO qd; Info: D/C drug and do not restart if hypersensitivity reaction suspected; do not cut/crush/chew tab or swallow tab whole

[3 mo and older, 14-19 kg]: Dose: 5 tabs PO qd; Info: D/C drug and do not restart if hypersensitivity reaction suspected; do not cut/crush/chew tab or swallow tab whole

[3 mo and older, 20-24 kg]: Dose: 6 tabs PO qd; Info: D/C drug and do not restart if hypersensitivity reaction suspected; do not cut/crush/chew tab or swallow tab whole

renal dosing

[see below]: CrCl 30-49: avoid use if lamivudine-related toxicities, dose adjustment not possible with fixed-dose combo, otherwise no adjustment; CrCl <30: avoid use, dose adjustment not possible with fixed-dose combo

HD/PD: avoid use, dose adjustment not possible with fixed-dose combo

hepatic dosing

[see below]: Child-Pugh Class A: avoid use, dose adjustment not possible with fixed-dose combo; Child-Pugh Class B or C: contraindicated

Drugs

Classes

Drug Names

Select a medication above to begin.